

Follicular lymphoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/FBA900FE8344EN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,500.00 (Single User License)

ID: FBA900FE8344EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Follicular lymphoma - Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Follicular lymphoma Understanding

Follicular lymphoma: Overview

Follicular lymphoma is the most common type of low-grade non-Hodgkin lymphoma. It can develop at any age, but it is more common in people over 60. In most cases, there is no known cause for follicular lymphoma. Some genetic changes are common in follicular lymphoma, but scientists don't know what causes them. There is not normally any family history of follicular lymphoma. Follicular lymphoma is usually very slow-growing so symptoms develop gradually over time. Many people have few symptoms and some have none at all. Sometimes follicular lymphoma is noticed during tests for a different health issue. However, follicular lymphoma can be very variable and some people might have faster-growing follicular lymphoma that causes more symptoms.

'Follicular lymphoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Follicular lymphoma pipeline landscape is provided which includes the disease overview and Follicular lymphoma treatment guidelines. The assessment part of the report embraces, in depth Follicular lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Follicular lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Follicular lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Follicular lymphoma.

Follicular lymphoma Emerging Drugs Chapters

This segment of the Follicular lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Follicular lymphoma Emerging Drugs

Pembrolizumab: Merck & Co

Pembrolizumab is a monoclonal antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally responsible for preventing the immune system from attacking the body's own tissues; it is a so-called immune checkpoint. Normally, the PD-1 receptor on activated T-cells binds to ligands PD-L1 or PD-L2 on other cells, deactivating a potential T-cell-mediated immune response against normal cells in the body. Currently, it is in phase II stage of development to treat Follicular lymphoma.

Mosunetuzumab: Genentech

Mosunetuzumab is an investigational CD20xCD3 T-cell engaging bispecific designed to target CD20 on the surface of B-cells and CD3 on the surface of T-cells. This dual targeting activates and redirects a patient's existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. Mosunetuzumab has a structure similar to that of a natural human antibody in that it has two 'Fab' regions, but is different from naturally-occurring antibodies in that one 'Fab' region targets CD20 and the other 'Fab' region targets CD3. A robust clinical development programme for mosunetuzumab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with CD20-positive B-cell non-Hodgkin lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma, and other blood cancers.

Tafasitamab: Incyte Corporation

Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).

Further product details are provided in the report.....

Follicular lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Follicular lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Follicular lymphoma

There are approx. 50+ key companies which are developing the therapies for Follicular lymphoma. The companies which have their Follicular lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genentech.

Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Follicular lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Follicular lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Follicular lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follicular lymphoma drugs.

Follicular lymphoma Report Insights

Follicular lymphoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Follicular lymphoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Follicular lymphoma drugs?

How many Follicular lymphoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Follicular lymphoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Follicular lymphoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Follicular lymphoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Merck & Co

Genentech

Incyte Corporation

Syndax Pharmaceuticals

Dr Reddy's Laboratories

Novartis

ADC Therapeutics

Xynomic Pharmaceuticals

Cho Pharma Inc.

Janssen

XEME Biopharma Inc.

Shanghai Yingli Pharmaceutical

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Beijing Mabworks Biotech Co., Ltd.

Archigen Biotech

Hutchison Medipharma Limited

Nordic Nanovector

Xynomic Pharmaceuticals

TG Therapeutics

BeiGene

Allogene Therapeutics

MEI Pharma, Inc.

Pfizer

Innovent Biologics (Suzhou) Co. Ltd.

Enterome

AstraZeneca

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Takeda

Bristol-Myers Squibb

TCR2 Therapeutics

Key Products

Pembrolizumab

Mosunetuzumab

Tafasitamab

Entinostat

DRL_RI

Tisagenlecleucel

Loncastuximab Tesirine

Abexinostat

CHO-H01

Ibrutinib

Oncoquest-L vaccine

YY-20394

TQ-B3525

MIL62

SAIT101

HMPL-689

Betalutin

Abexinostat

Ublituximab

Zanubrutinib

ALLO-501

Zandelisib

PF-06821497

IBI376

EO2463

Acalabrutinib

SHC014748M

TAK-659

Nivolumab

TC 110

Contents

- Introduction
- Executive Summary
- Follicular lymphoma: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- Mosunetuzumab: Genentech
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Pembrolizumab: Merck & Co
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....

- Early Stage Products (Phase I)
 - Comparative Analysis
- ALLO-501: Allogene Therapeutics
 - Product Description
 - Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....

Inactive Products
Comparative Analysis
Follicular lymphoma Key Companies
Follicular lymphoma Key Products
Follicular lymphoma- Unmet Needs
Follicular lymphoma- Market Drivers and Barriers
Follicular lymphoma- Future Perspectives and Conclusion
Follicular lymphoma Analyst Views
Follicular lymphoma Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Follicular lymphoma

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Follicular lymphoma
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Follicular lymphoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/FBA900FE8344EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FBA900FE8344EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970